Year: 2025

L’ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20% Clichy, December 8th, 2025 – L’Oréal today announces the acquisition of an additional 10% in Galderma Group AG from a consortium led by EQT, which includes Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd. (all acting in coordination as sellers) for an undisclosed amount. The transaction brings L’Oréal ownership of Galderma’s share capital to 20%. In connection with the increased investment, the board of Directors of Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the consortium led by EQT, as from the 2026 Annual General Meeting. L’Oréal’s increased strategic investment in Galderma confirms the solid growth journey...

Svitzer Nobbys TRAnsverse 3200Pictured: A TRAnsverse 3200 tug. Svitzer’s agreement with Cochin Shipyard covers the related TRAnsverse 2600e electric tugsSVITZER BarringtonSvitzer Barrington operating in AustraliaKasper Karlsen COOKasper Karlsen, Svitzer’s Chief Operating OfficerCochin, India and Copenhagen, Denmark – 8 December 2025. Svitzer, a leading global towage provider, and Cochin Shipyard Limited (CSL), India’s largest public sector shipyard, have signed a shipbuilding agreement for four 26-metre electric TRAnsverse (“TRAnsverse 2600e”) tugs to be constructed in India for Svitzer’s global fleet renewal and growth plans.  The agreement confirms a Letter of Intent signed in October 2025 at India Maritime Week and marks the move from intent to a contracted new build agreement.  Under the agreement,...

CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesCLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesCLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesCLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesEXECUTIVE SUMMARYVALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilitiescore focus on accelerating development of liquid long-acting drug delivery platforms existing RD&I teams will advance late-stage development programs without disruptionstrategic investment supported by the Singaporean Economic Development Board (EDB) five-year funded planMELBOURNE, Australia and SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE)...

SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the largest global provider of cloud- and carrier-neutral data center, colocation, and interconnection solutions and an Oracle Partner, today announced it will offer connectivity to an Oracle Cloud Infrastructure (OCI) FastConnect point-of-presence (PoP) within the Oracle Cloud Singapore West Region. In addition to the new connectivity, Digital Realty is also making an Oracle Solution Center available in Singapore through its global data center platform, PlatformDIGITAL®. The Oracle Solution Center will provide customers with a secure environment to design, test, and validate hybrid and AI architectures. It is the first in Singapore and reinforces the country’s role as a strategic regional hub for digital infrastructure and AI transformation. The new connectivity...

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA FactoryFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA FactoryFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA FactoryFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA FactoryThe first batch of knockdowns...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients 80% ORR achieved in newly diagnosed high-risk MDS/CMML Strong safety profile with no dose-limiting toxicities across all patient cohorts in 103-patient studyROCKVILLE, Md. and SUZHOU, China, Dec. 07, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax (APG-2575), a key investigational drug candidate in the Company’s pipeline, in combination...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2026 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. In addition, TAZVERIK® will be included in the first edition of the National Commercial Health Insurance Innovative Drug List (“Commercial Insurance Drug List”). ELUNATE® (fruquintinib) is included for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, in combination with TYVYT®...

SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following prior VEN-based treatmentMedian overall survival (mOS) of 8.9 months in the least pretreated patient cohort; across all cohorts, mOS was not yet reached in patients with one prior line of therapy vs historical benchmark of approximately 2.5 monthsSLS009 30 mg IV twice weekly added to AZA/VEN was safe and feasible, with no dose-limiting toxicities (DLTs) observedStudy expansion to evaluate SLS009 plus AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”),...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company’s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company’s website at https://ir.structuretx.com/events-presentations/events. To access the call by phone, participants should visit this link to receive dial-in details....

LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $100 million. The offering is expected...